Currently the Pfizer-Biontech (mRNA), Sinovac (inactivated virus) and Astrazeneca-Oxford (adenovirus-vector) COVID-19 vaccines are available for vaccination in HK. The American Association of Liver Disease has recently published consensus statements for COVID-19 vaccination in subjects with chronic liver disease (CLD). Patients with CLD have dysregulated innate and adaptive immune response that may be associated with vaccine hypo-responsiveness and there are no data as to whether these patients may respond differently to the various vaccines. The Humanity and Health Medical Center (HHMC) is an active participant of the HK government COVID-19 vaccination programs and patients with CLD follow-up at HHMC will have access to the three different vaccines. The aim of this prospective study is to compare the antibody response of CLD subjects to the Pfizer-Biontech (mRNA), Sinovac (inactivated virus) and Astrazeneca-Oxford (adenovirus-vector) COVID-19 vaccines.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
232
Intramuscular injection
Intramuscular injection
Intramuscular injection
Humanity & Health Medical Group Limited
Hong Kong, Hong Kong
Antibody response
Covid-19 Antibodies IgG titres at 4 weeks after second dose
Time frame: at 4 weeks after second dose
Antibody response
Covid-19 Antibodies IgG titres at one year after second dose
Time frame: at one year after second dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.